Oligonucleotides are short DNA or RNA molecules and have specific sequence of nucleotide residue, which makes an entire molecule. Oligonucleotides readily bind in specific sequencing manner to their respective DNA-RNA oligonucleotide to form duplex chain. Oligonucleotides are chemically synthesized molecular chains with phosphoramidite components of natural or chemically modified nucleosides and have wide range of applications in generic testing, research, and forensic.
The global oligonucleotide synthesis market is estimated to be valued at US$ 2,874.1 Million in 2020 and is expected to exhibit a CAGR of 11.3% during the forecast period (2020-2027).
Figure 1. Global Oligonucleotide Synthesis Market Share (%) in Terms of Value, By Region, 2020
Increasing research and development activities in the field of genomics and genetics is expected to propel the market growth during the forecast period
Research institutes and diagnostic centers have shifted their focus on genomics and genetics due, which has increased demand for high quality synthesized oligonucleotides in the market over the past few years. For instance, in July 2020, researchers of Rosalind Franklin University of Medicine and Science initiated a new therapeutic approach for treating Batten disease, a fatal neurodegenerative disease in children with the help of antisense oligonucleotides. These factors are expected to drive the global oligonucleotide synthesis market growth over the forecast period.
Expansion of manufacturing facilities by market players is expected to drive the market growth during the forecast period
Biotechnological companies are focusing on expanding their manufacturing facilities due to increasing demand for oligonucleotides from pharmaceutical companies. For instance, in March 2020, STA pharmaceuticals, a subsidiary of WuXi AppTech, announced inauguration of its large scale oligonucleotide active pharmaceutical ingredient manufacturing facility in China.
|Base Year:||2019||Market Size in 2020:||US$ 2,874.1 Mn|
|Historical Data for:||2016 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||11.3%||2027 Value Projection:||US$ 6,080.8 Mn|
Thermo Fisher Scientific, Sigma-Aldrich Corporation, GE Healthcare, Integrated DNA Technologies, Inc., TriLink Biotechnologies’, Inc, BioAutomation Corporation, Twist Bioscience, Shanghai SynTheAll Pharmaceutical Co., CUSABIO Technology LLC, Synbio Technologies, GENEWIZ, Eurofins Scientific, Agilent Technologies, Kaneka Eurogentec S.A., and LGC, Biosearch Technologies
|Restraints & Challenges:||
Global Oligonucleotide Synthesis Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus disease (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020.
According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 61.8 million cases and 1.4 million deaths due to coronavirus disease (COVID-19) were reported up till November 29, 2020 across the globe.
In order to deal with the COVID-19 pandemic, market players and government authorities are collaborating, in order to explore the oligonucleotide platform for the development of COVID-19 treatment. For instance, on April 28, 2020, Sarepta Therapeutics, Inc., and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), a department of defense’s lead laboratory for medical biological defense research entered into a cooperative research and development agreement (CRADA) to identify antisense oligonucleotides against SARS-CoV-2 for the potential treatment of COVID-19.
Figure 2. Global Oligonucleotide Synthesis Market Share (%) in Terms of Value, By Equipment & Services, 2020
Global Oligonucleotide Synthesis Market: Restraints
Natural oligonucleotides are composed of ribose or deoxyribose sugar phosphate as a base, which are quickly degraded in the body by nucleus. Moreover in generic testing, oligo-degradation can affect cell growth and cell proliferation. Furthermore, low quality of microarray generated oligonucleotide sequence is a major challenge in adopting microarray technology for oligonucleotide synthesis. These factors are expected to restrain the global oligonucleotide synthesis market growth.
Major players operating in the global oligonucleotide synthesis market include Thermo Fisher Scientific, Sigma-Aldrich Corporation, GE Healthcare, Integrated DNA Technologies, Inc., TriLink BioTechnologies, Inc, BioAutomation Corporation, Twist Bioscience, Shanghai SynTheAll Pharmaceutical Co., CUSABIO Technology LLC, Synbio Technologies, GENEWIZ, Eurofins Scientific, Agilent Technologies, Kaneka Eurogentec S.A., and LGC, Biosearch Technologies
Oligonucleotides are commonly used as primers for polymerase chain reaction (PCR), PCR assays, and panels for biologically related genes. Antisense oligonucleotides are used to reduce levels of protein synthesis by inhibiting mRNA processing or translation. Other uses of oligonucleotides include DNA sequencing, DNA microarrays, fluorescence in situ hybridization (FISH), and nucleic acid aptamers. Moreover, many pharmaceutical companies are focusing on developing nucleic acid-based therapeutics due to which the demand of oligonucleotide is increasing. Hence, market players are focusing on expanding their manufacturing facilities, which is expected to boost the market growth over the forecast period. For instance, in August 2020, Agilent Technologies Inc., announced the expansion of its state-of-the-art production facility in Frederick, Colorado, which develops manufactures oligos that hold potential to be used as treatments for diseases such as COVID-19, cardiovascular disease, cancer, rare and infectious diseases, and other conditions.
Key players are focusing on various inorganic growth strategies such as collaborations, partnerships and agreements, which is expected to propel the growth of the global oligonucleotide synthesis market during the forecast period. For instance, on August 05, 2020, Evotec SE, a drug discovery and development company entered into a strategic partnership with Secarna Pharmaceuticals GmbH & Co. KG, a drug discovery company, for the development of antisense oligonucleotide therapies.
Moreover, in November 2019, CSBio, a peptide and instrumentation manufacturing company entered into a collaboration with Sunresin, a supplier of ion exchange resin and absorption & separation resin for the development of an optimized polystyrene resin for commercial scale oligonucleotide synthesis.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.